Detecting hantavirus when serology is inconclusive

Method & sample types

Hantavirus infection typically presents with a nonspecific febrile prodrome, which means the diagnostic window during which IgM serology is reliably positive can lag several days behind symptom onset. The AMD Hantavirus PCR Kit detects viral RNA directly, which shortens that window: RNA is frequently detectable in serum or plasma before a robust antibody response has developed, and it remains detectable through the acute phase in patients who go on to develop haemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS).

Validated sample types are serum, plasma and, in selected clinical presentations, urine. Because viraemia is transient, a sample drawn late in the clinical course, particularly beyond the first one to two weeks, can revert to PCR-negative even in a genuine case, at which point paired serology becomes the more informative test. The practical guidance we give labs is straightforward: PCR in the acute, early-symptomatic window; serology (IgM, followed by IgG on a convalescent sample) once several days to weeks have passed.

Controls & interpretation

Every run carries an internal control target alongside the hantavirus-specific channel, so a negative result can be read with confidence that extraction and amplification both performed as expected. A failed internal control invalidates the run regardless of the hantavirus channel result, it should be repeated from a fresh extraction rather than reported.

Cross-reactivity with other rodent-borne or febrile-illness pathogens is not a significant concern for this assay design, since it targets conserved hantavirus sequence rather than a shared antigenic epitope, one of the reasons molecular testing is often preferred over serology alone when the differential is broad.

Workflow integration

The kit runs on standard Real-Time PCR platforms already common in clinical molecular labs, so it slots into an existing febrile-illness or zoonotic-panel workflow without new capital equipment. Turnaround from a validated extraction to a reportable result is consistent with same-day or next-day reporting, which matters clinically given how quickly HFRS/HPS can progress once symptomatic.